SK286233B6 - Isolation process of 14-hydroxycodeinone - Google Patents
Isolation process of 14-hydroxycodeinone Download PDFInfo
- Publication number
- SK286233B6 SK286233B6 SK395-2004A SK3952004A SK286233B6 SK 286233 B6 SK286233 B6 SK 286233B6 SK 3952004 A SK3952004 A SK 3952004A SK 286233 B6 SK286233 B6 SK 286233B6
- Authority
- SK
- Slovakia
- Prior art keywords
- hydroxycodeinone
- water
- separated
- reaction mixture
- ammonium hydroxide
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Vynález sa týka farmaceutickej výroby, izolácie 14-hydroxykodeinonu vzorca (I),The invention relates to pharmaceutical production, isolation of 14-hydroxycodeinone of formula (I),
i ktorý je intermediátom na prípravu silných analgetík (napr. Oxykodon) alebo morfmových antagonistov (Naltrexon), využívaných v medicínskej praxi.which is an intermediate for the preparation of potent analgesics (e.g. oxycodone) or morphine antagonists (Naltrexone) used in medical practice.
Doterajší stav technikyBACKGROUND OF THE INVENTION
14-Hydroxykodeinon (I) sa pripravuje transformáciou tebainu (II), prírodného alkaloidu izolovaného z rastliny Papaver somniferum L., alebo jeho analógov (III), kde R značí alkylový alebo benzylový zvyšok. 15 Pri tomto postupe (schéma 1) tebain (II), alebo jeho analóg v kyslom prostredí reaguje s peroxidom vodíka, peroxokyselinami, alebo inými oxidačnými látkami za vzniku 14/S-hydroxykodeinonu (I).14-Hydroxycodeinone (I) is prepared by transforming tebaine (II), a natural alkaloid isolated from Papaver somniferum L., or analogs (III) thereof, wherein R is an alkyl or benzyl residue. In this procedure (Scheme 1), thebaine (II), or an analogue thereof in an acidic environment, reacts with hydrogen peroxide, peracids, or other oxidizing agents to form 14 / S-hydroxycodeinone (I).
II R = CH3II R = CH 3
II
III R= ( H2C5H5 alebo CnH2n+lIII R = (H2C5H5 or Cn H2n + 1
Schéma 1Scheme 1
14-Hydroxykodeinon pripravený transformáciou dienolsilyléteru kodeinonu sa z reakčnej zmesi podľa US 6177567 čistí tak, že k reakčnej zmesi sa po skončení transformácie pridá hydrosiričitan sodný, zmes sa zahustí dosucha, následne sa pridá voda, toluén a octan etylový. Organická vrstva sa oddelí, extrahuje sa s 25 vodným roztokom kyseliny chlorovodíkovej, kyslá vodná vrstva sa oddelí, pridá sa hydroxid amónny a etyl acetát, zmes sa zahreje na teplotu 65 °C, vrstvy sa oddelia, etylacetátová sa zahustí dosucha, k zvyšku sa pridá 2-propanol, zmes sa mieša pri 5 až 10° C, vylúčené kryštály sa odfiltrujú, premyjú zmesou 2-propanolu s heptánom a vysušia.The 14-hydroxycodeinone prepared by transformation of codeenone dienolsilyl ether is purified from the reaction mixture according to US 6177567 by adding sodium bisulfite to the reaction mixture after transformation, concentrating to dryness, then adding water, toluene and ethyl acetate. The organic layer was separated, extracted with 25 aqueous hydrochloric acid solution, the acidic aqueous layer was separated, ammonium hydroxide and ethyl acetate were added, the mixture was heated to 65 ° C, the layers were separated, the ethyl acetate was concentrated to dryness, 2-propanol, the mixture is stirred at 5-10 ° C, the precipitated crystals are filtered off, washed with a 2-propanol-heptane mixture and dried.
Podľa Krassniga a spol. (Árch. Pharm. Pharm.Med. Chem. 329, 325-6 (1996)) sa reakčná zmes po trans30 formácii tebainu naliala na ľad, pridal sa hydroxid amónny, vylúčený 14-hydroxykodeinon sa extrahoval dichlormetánom, extraxt sa vysušil, zahustil a kryštalizoval zo zmesi dichlórmetán - etanol (1 : 1).According to Krassnig et al. (Ar. Pharm. Pharm.Med. Chem. 329, 325-6 (1996)), the reaction mixture was poured onto ice after trans30 formation of thebaine, ammonium hydroxide was added, the precipitated 14-hydroxycodeinone was extracted with dichloromethane, the extraxt dried, concentrated and crystallized from dichloromethane-ethanol (1: 1).
Seki I. (Takamine Kenmkyusho Nempo, 12, 52-5 (1960)) po oxidácii tebainu peroxidom vodíka v kyseline mravčej reakčnú zmes zriedil vodou, pridal acetón, hydrosiričitan sodný, upravil pH s hydroxidom amónnym na hodnotu 6.0, a následne pri pH vyzrážal 14-hydroxykodeinon hydroxidom amónnym. Produkt ďalej 35 nečistil, ale priamo použil na ďalšie spracovanie.Seki I. (Takamine Kenmkyusho Nempo, 12, 52-5 (1960)) after oxidation of thebaine with hydrogen peroxide in formic acid, the reaction mixture was diluted with water, added acetone, sodium bisulfite, adjusted pH with ammonium hydroxide to 6.0, and subsequently precipitated at pH 14-hydroxycodeinone with ammonium hydroxide. The product was not further purified, but used directly for further processing.
Ijima I. a spol. (Helv. Chim. Acta 60, 2135-7 (1977)) surový 14-hydroxykodeinon po vyzrážaní z reakčnej zmesi odfiltroval, zrazeninu premyl vodou, 95 %-ným etanolom a dietyléterom. Na rekryštalizáciu použili zmes etanolu s chloroformom. Podobný postup čistenia je opísaný aj v práci Hauser F. M., a spol. J. Med. Chem. 17, 1117 (1974) a Lutz R. E., Small L.: J. Org. Chem. 9, 220-233 (1939) s tým rozdielom, že posledne 40 uvedení autori surový 14-hydroxykodeinon rozpustili v chloroforme a prídavkom etanolu kryštalizovali produkt.Ijima I. et al. (Helv. Chim. Acta 60, 2135-7 (1977)) the crude 14-hydroxycodeinone was filtered off from the reaction mixture, washed with water, 95% ethanol and diethyl ether. For recrystallization they used a mixture of ethanol and chloroform. A similar purification procedure is also described in Hauser F. M., et al. J. Med. Chem. 17, 1117 (1974) and Lutz, R. E., Small L., J. Org. Chem. 9, 220-233 (1939) with the difference that the latter 40 dissolved the crude 14-hydroxycodeinone in chloroform and crystallized the product by adding ethanol.
Podľa Feldmana a Liutenberga (Ž. prikl. chim. 18, 716-717, (1945)) sa reakčná zmes po oxidácii tebainu alkalizuje hydroxidom amónnym, žltá zrazenina 14-hydroxykodeinonu sa odfiltruje, premyje horúcou vodou a použije na hydrogenáciu bez ďalšieho čistenia.According to Feldman and Liutenberg (J. Ex. Chim. 18, 716-717, (1945)), after the oxidation of thebaine, the reaction mixture was basified with ammonium hydroxide, the yellow 14-hydroxycodeinone precipitate was filtered off, washed with hot water and used for hydrogenation without further purification.
V spise WO9902529 sa reakčná zmes alkalizuje amoniakom, extrahuje chloroformom, fázy sa oddelia a zvyšok po oddestilovaní chloroformu z organickej vrstvy sa zahustí a použije na hydrogenáciu bez ďalšieho čistenia.In WO9902529, the reaction mixture is basified with ammonia, extracted with chloroform, the phases are separated and the residue after distillation of the chloroform from the organic layer is concentrated and used for hydrogenation without further purification.
Všetky uvedené spôsoby izolácie 14-hydroxykodeinonu majú nedostatok v tom, že reakciou peroxidu/peroxokyselín s tebainom alebo jeho analógmi sa pripraví 14-hydroxykodeinon znečistený príbuznými látkami, ako napr. 10-hydroxytebain, 10,14-dihydroxykodeinon, ťažko separovateľnými vedľajšími produktami a pod., ktoré sa uvedenými postupmi neodstránia, ale prenášajú sa do ďalších stupňov prípravy oxykodónu, a tak znižujú kvalitu produktu, resp. pri ďalšej purifikácii v poslednom kroku znižujú celkový výťažok procesu, a poskytuje nízky výťažok.All of the aforementioned methods of isolating 14-hydroxycodeinone have the drawback that by reacting peroxide / peracids with tebaine or analogs thereof, 14-hydroxycodeinone is contaminated with related substances such as e.g. 10-hydroxytebaine, 10,14-dihydroxycodeinone, hardly separable byproducts and the like, which are not removed by these processes but are carried forward to the next stages of the oxycodone preparation and thus reduce the product quality and / or the product quality. for further purification, in the final step, they reduce the overall yield of the process, and yield a low yield.
Uvedené nedostatky odstraňuje postup podľa tohto vynálezu.These drawbacks are overcome by the process of the present invention.
Podstata vynálezuSUMMARY OF THE INVENTION
Predmetom vynálezu je spôsob izolácie 14-Hydroxykodeinonu vzorca (I) z reakčnej zmesi získanej reakciou tebainu (II) alebo jeho analógov vzorca (III), kde R značí alkyl s počtom uhlíkov 2 až 5, alkylaryl výhodne benzyl, alebo metoxybenzyl, alyl,The present invention provides a process for the isolation of 14-hydroxycodeinone of formula (I) from a reaction mixture obtained by reacting thebaine (II) or analogues of formula (III) thereof, wherein R is an alkyl having 2 to 5 carbon atoms, alkylaryl preferably benzyl, or methoxybenzyl,
III R = CH2C6H5 alebo CnH2n+lIII R = CH 2 C 6 H 5 or C n H 2n + 1
I s peroxidom vodíka alebo peroxokyselinami, pri ktorom sa reakčná zmes po skončení konverzie tebainu, alebo analógov vzorca III alkalizuje prídavkom čpavku na hodnotu pH 9 až 10 pri teplote 0 až 10° C, vylúčená báza 14-hydroxykodeinonu sa extrahuje organickým rozpúšťadlom, výhodne dichlórmetánom, toluénom, alebo ich zmesou s nižšími alkoholmi s počtom uhlíkov 3 až 5, pričom pomer dichlórmetánu alebo toluénu a nižšieho alkoholu je výhodne 99 : 1 až 9 : I, organický extrakt sa oddelí a zahustí. 14-Hydroxykodeinón sa extrahuje vodným roztokom organickej kyseliny, napr. mravčej alebo octovej. Kyslá vodná vrstva obsahujúca 14-hydroxykodeinon sa oddelí, pH roztoku sa upraví prídavkom bázy, výhodne hydroxidom amónnym na hodnotu 9,0 až 10 a vylúčený 14-hydroxykodeinon sa oddelí, premyje vodou, zmesou acetón-voda a vysuší.Even with hydrogen peroxide or peracids, in which the reaction mixture is alkalinized to pH 9-10 at 0-10 ° C by addition of ammonia at the end of the conversion of thebaine or analogs of formula III, the precipitated 14-hydroxycodeinone base is extracted with an organic solvent, preferably dichloromethane , toluene, or a mixture thereof with lower alcohols having a carbon number of 3 to 5, wherein the ratio of dichloromethane or toluene to the lower alcohol is preferably 99: 1 to 9: 1, the organic extract is separated and concentrated. 14-Hydroxycodeinone is extracted with an aqueous solution of an organic acid, e.g. form or vinegar. The acidic 14-hydroxycodeinone-containing aqueous layer is separated, the pH of the solution is adjusted to 9.0-10 by the addition of a base, preferably ammonium hydroxide, and the precipitated 14-hydroxycodeinone is separated, washed with water, acetone-water and dried.
Výhodou uvedeného postupuje, že umožňuje získať produkt vysokej čistoty.The advantage of this process is that it makes it possible to obtain a product of high purity.
Nasledujúce príklady podrobnejšie opisujú spôsob podľa patentu, v žiadnom prípade však neznamenajú vymedzenie jeho rozsahu.The following examples describe the process of the patent in more detail, but do not in any way limit its scope.
Príklady uskutočnenia vy nálezuExamples of the invention
Príklad 1Example 1
10,0 g tebainu (31,6 mmol) sa rozpustí vo vodnom roztoku kyseliny šťaveľovej (2,2 g kyseliny šťaveľovej (17,53 mmol) a 14,0 ml vody) pri teplote 15 °C. Po rozpustení tebainu sa pridá sa zmes 4,6 g kyseliny mravčej 88 %-nej (101,3 mmol) a 4,4 ml 30 %-ného peroxidu vodíka (43,14 mmol) Reakčná zmes sa mieša pri teplote 25 °C až do úplnej konverzie tebainu (hodnotí sa kapilárnou elektroforézou; kapilára 50 cm x 0,05 mm, elektrolyt 100 mM TRIS/fosfát, pH 2,7, 5 mM dimetoxy-0-cyklodextrínu, teplota 25 °C 30 kV; migračný čas tebainu 5,6 min.). Po skončení reakcie sa rekčná zmes ochladí na teplotu 5 °C, pridá sa kone, hydroxid amónny do pH 9,2. Vzniknutá suspenzia sa extrahuje dichlórmetánom (100 ml), organická fáza sa oddelí, premyje vodou a nasýteným roztokom NaCl. Dichlórmetánový roztok sa extrahuje vodným roztokom kyseliny mravčej (5 g kyseliny mravčej v 60 ml vody), vodný kyslý extrakt sa oddelí, vymieša sa s aktívnym uhlím, suspenzia sa filtruje, číry filtrát sa ochladí na teplotu 5 °C a za miešania sa prídavkom kone, hydroxidu amónneho upraví pH na 9,2, vylúčené kryštály 14-hydroxykodeinon sa odfiltrujú, premyjú vodou, zmesou acetón-voda (1 : 1) a vysušia. Týmto postupom sa získa 9,0 g 14-hydroxykodeinonu, obsah (99,5 %), obsah vody: 0,0648 %, sušina: 99,97 %, teplota topenia: 271,6 až 273,1 °C , množstvo tebainu: 0,0 %.Dissolve 10.0 g of thebaine (31.6 mmol) in an aqueous solution of oxalic acid (2.2 g of oxalic acid (17.53 mmol) and 14.0 mL of water) at 15 ° C. After dissolution of thebaine, a mixture of 4.6 g of 88% formic acid (101.3 mmol) and 4.4 ml of 30% hydrogen peroxide (43.14 mmol) was added. The reaction mixture was stirred at 25 ° C to to complete conversion of tebaine (assessed by capillary electrophoresis; capillary 50 cm x 0.05 mm, electrolyte 100 mM TRIS / phosphate, pH 2.7, 5 mM dimethoxy-O-cyclodextrin, temperature 25 ° C 30 kV; migration time tebain 5 , 6 min.). After completion of the reaction, the reaction mixture was cooled to 5 ° C, horses, ammonium hydroxide added to pH 9.2. The resulting suspension is extracted with dichloromethane (100 mL), the organic phase is separated, washed with water and saturated NaCl solution. The dichloromethane solution was extracted with an aqueous formic acid solution (5 g formic acid in 60 mL water), the aqueous acidic extract was separated, mixed with charcoal, the suspension was filtered, the clear filtrate was cooled to 5 ° C and stirred with the addition of The ammonium hydroxide was adjusted to pH 9.2, the precipitated 14-hydroxycodeinone crystals were filtered off, washed with water, acetone-water (1: 1) and dried. This gives 9.0 g of 14-hydroxycodeinone, content (99.5%), water content: 0.0648%, solids: 99.97%, melting point: 271.6-273.1 ° C, amount of thebaine : 0.0%.
Príklad 2Example 2
Reakčná zmes pripravená postupom uvedeným v príklade 1 sa ochladí na teplotu 5 °C, prídavkom 25 %-ného hydroxidu amónneho sa pH upraví na hodnotu 9,3, suspenzia sa extrahuje toluénom (100 ml), toluénová vrstva sa premyje vodou, nasýteným roztokom NaCl, a extrahuje sa vodným roztokom kyseliny octovej (5 g v 100 ml vody). Kyslá vodná fáza sa oddelí, prečistí karborafínom a prefiltruje sa. K prečistenej kyslej vodnej fáze sa po ochladení na teplotu 10 °C pridá 100 ml acetónu a prídavkom koncentrovaného hydroxidu amónneho do pH 9,5 sa vyzráža 14-hydroxykodeinon. Vylúčené kryštály 14-hydroxykodeinonu sa odfiltrujú, premyjú vodou, zmesou acetón - voda (1 : 1) a vysušia. Týmto postupom sa získalo 9,1 g 14-hydroxykodeinonu, obsah 99,9 %), voda: 0,06 %, sušina: teplota topenia: 274,2 °C; tebain: 0,0 %.The reaction mixture prepared as in Example 1 was cooled to 5 ° C, adjusted to pH 9.3 by addition of 25% ammonium hydroxide, extracted with toluene (100 mL), washed with water, saturated NaCl solution. , and extracted with aqueous acetic acid (5 g in 100 mL water). The acidic aqueous phase was separated, washed with carboraffin and filtered. After cooling to 10 ° C, 100 ml of acetone are added to the purified acidic aqueous phase and 14-hydroxycodeinone is precipitated by addition of concentrated ammonium hydroxide to pH 9.5. The precipitated 14-hydroxycodeinone crystals are filtered off, washed with water, acetone-water (1: 1) and dried. This gave 9.1 g of 14-hydroxycodeinone (99.9% content), water: 0.06%, solids: mp: 274.2 ° C; tebaine: 0.0%.
Príklad 3Example 3
500,0 g tebainu (1.58 mol) sa rozpustí vo vodnej kyseline šťaveľovej (110,0 g kyseliny šťaveľovej (867,5 mmol) a 700,0 ml vody pri teplote 15 °C, za miešania sa pridá zmes 120 g kyseliny mravčej 88 %-nej, (2.20 mol) a 220 ml 30%-ného peroxidu vodíka (2.16 mol) Reakčná zmes sa mieša pri teplote 25 °C až do úplnej konverzie tebainu (hodnotí sa kapilárnou elektroforézou). Reakčná zmes sa ochladí na teplotu 10 °C a prídavkom kone, hydroxidu amónneho sa upraví pH na hodnotu 9,2, suspenzia sa extrahuje zmesou toluén - 2-propanol (94 : 6) 2 x po 250 ml. Spojené organické fázy sa premyjú vodou a nasýteným vodným roztokom NaCl. Organická vrstva sa extrahuje vodným roztokom kyseliny mravčej (100 ml v 1500 ml vody), kyslý vodný extrakt sa spracuje s aktívnym uhlím, prefiltruje sa cez kremelinu, filtrát sa ochladí na teplotu 5 °C, prídavkom koncentrovaného hydroxidu amónneho do pH 9.6 sa vyzráža 14-Hydroxykodeinon. Vylúčené kryštály sa odfiltrujú, premyjú studenou vodou a nakoniec zmesou acetón - voda (1 : 1) a vysušia sa za vákua pri teplote 50 °C. Týmto postupom sa získalo 430 g 14-hydroxykodeinonu, obsah (99,3 %), obsah tebainu 0,021 %, obsah vody 0,14%.Dissolve 500.0 g of tebaine (1.58 mol) in aqueous oxalic acid (110.0 g of oxalic acid (867.5 mmol) and 700.0 ml of water at 15 ° C, add 120 g of formic acid with stirring. (2.20 mol) and 220 ml of 30% hydrogen peroxide (2.16 mol) The reaction mixture was stirred at 25 ° C until complete conversion of thebaine (assessed by capillary electrophoresis) was cooled to 10 °. The pH of the solution was adjusted to 9.2 with the addition of horse ammonium hydroxide, the suspension was extracted with toluene-2-propanol (94: 6) 2 x 250 mL each, and the combined organic phases were washed with water and saturated aqueous NaCl. extract with aqueous formic acid solution (100 ml in 1500 ml of water), treat the acidic aqueous extract with charcoal, filter through diatomaceous earth, cool the filtrate to 5 ° C, precipitate 14-Hydroxycodeinone by adding concentrated ammonium hydroxide to pH 9.6 The precipitated crystals were filtered off Wash with cold water and finally with acetone-water (1: 1) and dry under vacuum at 50 ° C. This gave 430 g of 14-hydroxycodeinone, content (99.3%), thebaine content 0.021%, water content 0.14%.
Príklad 4Example 4
100,0 g (0,26 mol) 6-O-benzyltebainu sa za chladenia a miešania pridá do roztoku pripraveného z 22,0 g (0,174 mol) kyseliny šťaveľovej rozpustenej v 140 ml vody. Potom sa pridá 23,0 g (0,44 mol) 88 %-nej kyseliny mravčej, pri teplote cca 15 °C. Po rozpustení tebainu sa reakčná zmes ohreje na teplotu 20 °C, pridá sa 44,0 ml (0,17 mol) 30 %-ného peroxidu vodíka. A reakčná zmes sa mieša pri teplote 25 °C (konverzia tebainu sa sleduje kapilárnou elektroforézou, podmienky uvedené v príklade 1). Reakčná zmes sa ochladí na teplotu 5 °C prídavkom hydroxidu amónneho sa upraví pH na hodnotu 9,5, vzniknutá suspenzia sa extrahuje zmesou toluén - n-butanol 97 : 3 (2-krát po 120 ml), spojené extrakty sa premyjú vodou, organická vrstva sa zahustí na 100 ml, destilačný zvyšok sa extrahuje vodným roztokom kyseliny mravčej (250 ml, 15 % ), kyslá vodná fáza sa spracuje s karborafínom a po 30 minútach miešania sa prefiltruje cez kremelinu, filtrát sa ochladí na teplotu 5 °C, prídavkom koncentrovaného hydroxidu amónneho sa upraví pH na hodnotu 9,1, vylúčený 14-hydroxykodeinon sa odfiltruje, premyje studenou vodou, zmesou acetón - voda (1 : 1) a vysuší pri zníženom tlaku. Týmto postupom sa získalo 78,2 g 14-hydroxykodeinonu, sušina 99,86 % obsah - 98,8 %, tebain 0,19 %.100.0 g (0.26 mol) of 6-O-benzyltebaine are added with cooling and stirring to a solution prepared from 22.0 g (0.174 mol) of oxalic acid dissolved in 140 ml of water. 23.0 g (0.44 mol) of 88% formic acid are then added at a temperature of about 15 ° C. After dissolution of thebaine, the reaction mixture was warmed to 20 ° C, and 44.0 mL (0.17 mol) of 30% hydrogen peroxide was added. And the reaction mixture was stirred at 25 ° C (conversion of thebaine was monitored by capillary electrophoresis, conditions set forth in Example 1). The reaction mixture is cooled to 5 ° C by addition of ammonium hydroxide, the pH is adjusted to 9.5, the resulting suspension is extracted with toluene-n-butanol 97: 3 (2 x 120 ml), the combined extracts are washed with water, organic concentrate to 100 ml, extract the residue with aqueous formic acid solution (250 ml, 15%), treat the acidic aqueous phase with carboraffin and, after stirring for 30 minutes, filter through diatomaceous earth, cool the filtrate to 5 ° C by adding of concentrated ammonium hydroxide is adjusted to pH 9.1, the precipitated 14-hydroxycodeinone is filtered off, washed with cold water, acetone-water (1: 1) and dried under reduced pressure. This procedure yielded 78.2 g of 14-hydroxycodeinone, dry matter 99.86% content - 98.8%, tebaine 0.19%.
Priemyselná využiteľnosťIndustrial usability
Predmet vynálezu je využiteľný pri príprave intermediátu pri výrobe farmaceutickej substancie oxykodon alebo morfínových antagonistov využívaných v medicínskej praxi.The present invention is useful in the preparation of an intermediate in the manufacture of a pharmaceutical substance oxycodone or morphine antagonists used in medical practice.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SK395-2004A SK286233B6 (en) | 2004-11-15 | 2004-11-15 | Isolation process of 14-hydroxycodeinone |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SK395-2004A SK286233B6 (en) | 2004-11-15 | 2004-11-15 | Isolation process of 14-hydroxycodeinone |
Publications (2)
Publication Number | Publication Date |
---|---|
SK3952004A3 SK3952004A3 (en) | 2006-08-03 |
SK286233B6 true SK286233B6 (en) | 2008-05-06 |
Family
ID=36954075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SK395-2004A SK286233B6 (en) | 2004-11-15 | 2004-11-15 | Isolation process of 14-hydroxycodeinone |
Country Status (1)
Country | Link |
---|---|
SK (1) | SK286233B6 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9062062B1 (en) | 2013-12-18 | 2015-06-23 | Cody Laboratories, Inc. | Synthesis of oxycodone hydrochloride |
US9090620B2 (en) | 2013-12-18 | 2015-07-28 | Cody Laboratories, Inc. | Preparation of 14-hydroxycodeinone sulfate |
US10227354B2 (en) | 2013-12-18 | 2019-03-12 | Cody Laboratories, Inc. | Conversion of oxycodone base to oxycodone hydrochloride |
US10428079B2 (en) * | 2014-01-15 | 2019-10-01 | Rhodes Technologies | Process for improved oxycodone synthesis |
US11390627B2 (en) | 2012-07-16 | 2022-07-19 | Rhodes Technologies | Process for improved opioid synthesis |
-
2004
- 2004-11-15 SK SK395-2004A patent/SK286233B6/en not_active IP Right Cessation
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11390627B2 (en) | 2012-07-16 | 2022-07-19 | Rhodes Technologies | Process for improved opioid synthesis |
US9062062B1 (en) | 2013-12-18 | 2015-06-23 | Cody Laboratories, Inc. | Synthesis of oxycodone hydrochloride |
US9090620B2 (en) | 2013-12-18 | 2015-07-28 | Cody Laboratories, Inc. | Preparation of 14-hydroxycodeinone sulfate |
US9108976B2 (en) | 2013-12-18 | 2015-08-18 | Cody Laboratories, Inc. | Preparation of 14-hydroxycodeinone sulfate |
US9233972B2 (en) | 2013-12-18 | 2016-01-12 | Cody Laboratories, Inc. | Preparation of 14-hydroxycodeinone sulfate |
US9309257B2 (en) | 2013-12-18 | 2016-04-12 | Cody Laboratories, Inc. | Preparation of oxycodone base form 14-hydroxycodeinone sulfate |
US10227354B2 (en) | 2013-12-18 | 2019-03-12 | Cody Laboratories, Inc. | Conversion of oxycodone base to oxycodone hydrochloride |
US10428079B2 (en) * | 2014-01-15 | 2019-10-01 | Rhodes Technologies | Process for improved oxycodone synthesis |
US10844072B2 (en) | 2014-01-15 | 2020-11-24 | Rhodes Technologies | Process for improved oxycodone synthesis |
Also Published As
Publication number | Publication date |
---|---|
SK3952004A3 (en) | 2006-08-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CZ295477B6 (en) | Process for preparing tolterodine | |
ES2273328T3 (en) | OXICODONE PREPARATION METHOD. | |
EP2125821A1 (en) | Process for the preparation of sildenafil | |
US2956998A (en) | Adenine derivatives and process | |
WO2010140168A1 (en) | Improved process for preparing temozolomide | |
WO2009010987A1 (en) | An improved process for the preparation of pure palonosetron hydrochloride | |
US8399671B2 (en) | Methods for producing hydrocodone, hydromorphone or a derivative thereof | |
SK286233B6 (en) | Isolation process of 14-hydroxycodeinone | |
EP2571857B1 (en) | Process for the preparation of pyrimidinone compounds | |
RU2387656C2 (en) | Method for synthesis of galantamine hydrobromide | |
TW201802103A (en) | Preparation method of obeticholic acid and intermediates thereof | |
KR101485418B1 (en) | A synthetic method of high purity mirtazapine | |
CA3163243A1 (en) | Sstr5 antagonists | |
JP2020070296A (en) | Method for producing linagliptin | |
DE69407789T2 (en) | METHOD FOR PRODUCING (S) -4-AMINOHEPTA-5,6-DIENCARBONIC ACID AND INTERMEDIATES | |
KR100856133B1 (en) | Improved process for preparing atorvastatin | |
JPH02289581A (en) | Improved method for preparing optically pure hetrazepines | |
EP1572696B1 (en) | Process for the direct preparation of 5-alkoxy and 5-acyloxy analogues of campthothecins or mappicene ketones | |
SU351369A1 (en) | METHOD OF OBTAINING ALKALOIDS | |
WO2023205164A1 (en) | Processes for the preparation of finerenone | |
US6872829B2 (en) | Process for the direct preparation of 5-alkoxy and 5-acyloxy analogues of camptothecins or mappicene ketones | |
Scheiber et al. | Short synthesis of 2, 3, 4, 5-tetrahydrocytisine | |
CA3226626A1 (en) | Crystal form of compound represented by formula i, and preparation therefor and application thereof | |
JP2023522800A (en) | Process for the manufacture of Tofacitinib and its intermediates | |
CN111808040A (en) | Synthesis method of multi-configuration 2-oxo-oxazolidine-4-carboxylic acid compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TE4A | Change of owner's address |
Owner name: ZENTIVA, A.S., BRATISLAVA, SK Effective date: 20130927 |
|
PC4A | Assignment and transfer of rights |
Owner name: SANECA PHARMACEUTICALS A. S., HLOHOVEC, SK Free format text: FORMER OWNER: ZENTIVA, A.S., BRATISLAVA, SK Effective date: 20131001 |
|
MM4A | Patent lapsed due to non-payment of maintenance fees |
Effective date: 20131115 |